FierceBiotech's Maureen Martino has produced a "special report" that four biotech drugs poised for approval later this year could be "the next generation of biologic blockbusters" -- that is, treatments that not only pull in more than $1 billion in annual sales, but which "could offer real breakthroughs for patients"...
By 2012, sales of monoclonalantibodies will represent nearly 50% of oncology drug sales, according to anew study by Cutting Edge Information. Successful brands such as Rituxan, Herceptin and Erbitux are all expectedto grow by anywhere from 23% to 80% by 2013. Furthermore, there areseveral monoclonal antibodies, such as Amgen's...
Study Met Primary Endpoint of Reducing New Vertebral Fractures and Secondary Endpoints of Reducing Time to First Non-Vertebral and Hip Fractures Adverse Events Similar to Placebo THOUSAND OAKS, Calif. -- Amgen (NASDAQ: AMGN) today announced findings from the pivotal fracture trial evaluating its RANK Ligand inhibitor,...
Thousand Oaks based Amgen Inc. saw a 7.4% rise in its stock price over the two weeks ending July 16. On July 11, the company announced that it had reached an agreement to settle its outstanding antitrust litigation with Ortho Biotech Products L.P. On July 14, the company also announced...
Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. Monoclonal Antibodies Report: 2008 Update - Detailed analysis of the monoclonal antibody segment, encompassing market dynamics, key therapy areas, technology and target types through to 2013, evaluating the...
CHICAGO -- Zacks Equity Research highlights ConocoPhillips (NYSE: COP) as the Bull of the Day and General Motors (NYSE: GM) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Amgen, Inc. (Nasdaq: AMGN), Web.com (Nasdaq: WWWW) and Oxford Industries (NYSE: OXM). ...
Giant Cell Tumor is a Rare Bone Tumor Afflicting Younger Adults For Which Few Treatment Options Exist ABSTRACT NUMBER: 10500 CHICAGO -- Amgen (NASDAQ:AMGN) today announced interim results of an open-label Phase 2 study demonstrating a positive response rate to administration of denosumab in subjects with...
Phase 2 Study of Patients Previously Treated with IV Bisphosphonates Showed Denosumab Reduced Bone Resorption and Skeletal-Related Events Comparison of Phase 2 Studies Showed Consistent Reduction of Bone Resorption with Denosumab in either Bisphosphonate-Naive or -Treated Patients Sub-group Analysis of Phase 3 Study Showed Denosumab Increased...
THOUSAND OAKS, Calif. -- Amgen (NASDAQ:AMGN) will webcast its investor meeting at the upcoming American Society of Clinical Oncology ASCO Conference on Sunday, June 1 at 8 p.m. Central Time. Members of Amgen's scientific and management team will participate at the meeting. The company plans to highlight key compounds in...
Phase 3 Study Showed Bone Mineral Density Gains at All Skeletal Sites Measured with Denosumab Administration BARCELONA, Spain -- Amgen (NASDAQ: AMGN) today announced complete results from a head-to-head, double-blind study comparing the effects of twice-yearly subcutaneous injections of denosumab versus weekly oral doses of alendronate (FOSAMAX([R])) on...
THOUSAND OAKS, Calif. -- Amgen (NASDAQ:AMGN) today announced that it will hold a conference call on Wednesday, May 28, 2008, beginning at 8 a.m. Eastern Time to discuss the results of the denosumab Phase 3 head-to-head study versus alendronate (the "141" study) at the upcoming European Symposium on Calcified Tissues...
Patients Transitioned from Alendronate to Denosumab Therapy Achieved Superior Gains in Bone Mineral Density Versus Those Continuing on Alendronate Therapy THOUSAND OAKS, Calif. -- Amgen (NASDAQ: AMGN) today announced findings from a head-to-head, double-blind trial comparing the effects of denosumab in post-menopausal women with low bone mass transitioned...
New Data from Denosumab, Vectibix([R]) and Mid-Stage Pipeline Demonstrate Progress of Oncology Portfolio THOUSAND OAKS, Calif. -- Amgen (NASDAQ:AMGN) today announced it will present new data from the Company's oncology portfolio on both approved and investigational cancer therapies at the 2008 American Society of Clinical Oncology ASCO Annual...
Overall Incidence of Adverse Events Similar Between Denosumab and Placebo Groups THOUSAND OAKS, Calif. -- Amgen (NASDAQ: AMGN) today announced the publication of results from its 24-month, 332-patient Phase 3 pivotal study in women with early and late stage postmenopausal osteoporosis in the Journal of Clinical Endocrinology and...
SAN FRANCISCO -- A number of novel treatments for osteoporosis are under investigation, and one of them might even provide a cure for the disease, Dr. Steven R. Cummings said at a meeting on osteoporosis sponsored by the University of California, San Francisco. Dr. Cummings, director of the...
THOUSAND OAKS, Calif. -- Amgen (NASDAQ:AMGN) today announced findings from a head-to-head, double-blind study comparing the effects of twice-yearly subcutaneous injections of denosumab versus weekly oral doses of alendronate (FOSAMAX([R])) on bone mineral density BMD in postmenopausal women with low bone mineral density. The study met primary and all secondary...
SAN ANTONIO -- The novel bone-strengthening agent denosumab markedly increased bone mineral density at both trabecular and cortical sites throughout the skeleton in its first phase III clinical trial in breast cancer patients on adjuvant aromatase inhibitor therapy, Dr. Georgiana K. Ellis reported at the annual San Antonio Breast Cancer...
A Study Evaluating Twice Yearly Dosing with Denosumab Met All Primary and Secondary Endpoints SAN ANTONIO -- Amgen (NASDAQ:AMGN) today announced results of the first Phase 3 pivotal study to complete in the denosumab oncology development program. The study evaluated denosumab's effect on bone density across the skeleton...
Powerful, Dell is built to fit your business needs Customized systems, experts trained in small business, 24/7/365 support, and powerful, reliable technology. Dell, big results for small business.
With AT&T Tech Support 360, you'll have certified, U.S. based technicians on call 24/7 to help keep your computers, connections, software and peripherals up to speed for just 82¢ a day.
